Nancy Lin is a Respiratory physician. ClinicalTrials.gov lists 15 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 N Wolfe St
Baltimore, MD 212870005
Telephone
410-955-8985Provider last certified this registry record 8 Oct 2024.
Clinical trials
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Sponsor: Dana-Farber Cancer Institute
- DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Sponsor: Nancy Lin, MD
- STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Sponsor: Dana-Farber Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Mallinckrodt Hospital Products Inc.Program year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
39.1%Corticosteroid39.1%Prednisone100%Part D<11 patientsCancer & immunology
32.6%Folate Analog Metabolic Inhibitor32.6%Methotrexate100%Part D<11 patientsAnti-infectives
28.3%Azole Antifungal28.3%Fluconazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- MicroRNA as Diagnostic and Prognostic Biomarkers in Sarcoidosis
Johns Hopkins University
FY2026$182,165K23HL163313 - MicroRNA as Diagnostic and Prognostic Biomarkers in Sarcoidosis
Johns Hopkins University
FY2025$182,165K23HL163313 - MicroRNA as Diagnostic and Prognostic Biomarkers in Sarcoidosis
Johns Hopkins University
FY2025$74,670K23HL163313
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”